Get the latest tech news
Breast cancer cure rates almost doubled in combo therapy trial | A phase 3 clinical trial has shown that adding a targeted immunotherapy drug to chemotherapy dramatically improved the cure rate for patients with the most common kind of breast cancer.
A phase 3 clinical trial has shown that adding a targeted immunotherapy drug to chemotherapy dramatically improved – almost doubled – the cure rate for patients with the most common kind of breast cancer. The findings suggest adopting a new treatment paradigm for the disease.
A phase 3 clinical trial has shown that adding a targeted immunotherapy drug to chemotherapy dramatically improved – almost doubled – the cure rate for patients with the most common kind of breast cancer. “These patients are considered to be likely cured because their tumor was removed and samples of breast and lymph node tissue collected at the same time also show no detectable cancer cells,” said Professor Sherene Loi, who led the trial and is the study’s lead and corresponding author. “Overall, these results represent a new milestone in the neoadjuvant treatment of ER+/HER2– BC [breast cancer], because there have been intensive but thus far unsuccessful efforts to improve pCR rates in this patient population,” they said.
Or read this on r/tech
